This is a non-core endpoint: only basic statistics are computed.
See these related core endpoints for full statistics:
Malignant neoplasm of other and ill-defined digestive organs, excluding all cancers (controls excluding all cancers)
C3_DIGESTIVE_ORGANS_NAS_EXALLC
No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
3 out of 7 registries used, show all original rules. |
570 |
4. Check minimum number of eventsNone |
570 |
5. Include endpointsNone |
570 |
6. Filter based on genotype QC (FinnGen only) |
570 |
Control definitions (FinnGen only)
- Control exclude
- C3_CANCER, C3_CANCER_WIDE_EXALLC
Extra metadata
- First used in FinnGen datafreeze
- DF12
Similar endpoints
↥List of similar endpoints to
Malignant neoplasm of other and ill-defined digestive organs, excluding all cancers (controls excluding all cancers)
based on the number of shared cases.
Similar with more cases:
- Malignant neoplasm of digestive organs, excluding all cancers (controls excluding all cancers)
- Malignant neoplasm, excluding all cancers (controls excluding all cancers)
- Malignant neoplasm, wide definition for exclusion
- Malignant neoplasm, wide definition for exclusion, excluding all cancers (controls excluding all cancers)
- Any event in hilmo or specialist outpatient
Similar with less cases:
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 570 | 276 | 294 |
| Unadjusted period prevalence (%) | 0.11 | 0.09 | 0.13 |
| Median age at first event (years) | 70.81 | 71.41 | 70.26 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 231
- Matched controls
- 2307
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
130
Kela drug reimbursment
Malignant tumour
+∞
123.2
107
*
C26.9
ICD-10 Finland
Malignant neoplasm: Ill-defined sites within the digestive system
+∞
88.3
79
*
8140/3-C26.9
ICD-O-3
Adenocarcinoma, NOS, of gastrointestinal tract, NOS
+∞
85.9
77
*
C79.8
ICD-10 Finland
Secondary malignant neoplasm of other specified sites
+∞
61.2
56
*
Z51.5
ICD-10 Finland
Palliative care
35.7
60.8
79
33
H02AB02
ATC
dexamethasone; systemic
85.7
57.8
63
10
A03FA01
ATC
metoclopramide; systemic, rectal
14.6
56.2
105
124
A04AA02
ATC
granisetron; systemic, transdermal
349.6
55.8
54
*
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
661.2
54.9
52
*
C78.7
ICD-10 Finland
Secondary malignant neoplasm of liver and intrahepatic bile duct
+∞
50.9
47
*
C26.0
ICD-10 Finland
Malignant neoplasm: Intestinal tract, part unspecified
+∞
41.9
39
*
N02AA05
ATC
oxycodone; systemic
8.7
39.5
99
183
L01BC06
ATC
capecitabine; oral
+∞
38.6
36
*
JN4BD
NOMESCO Finland
Extensive body CT
17.2
38.0
62
48
8000/3-C26.9
ICD-O-3
Neoplasm, malignant of gastrointestinal tract, NOS
+∞
37.5
35
*
C78.6
ICD-10 Finland
Secondary malignant neoplasm of retroperitoneum and peritoneum
+∞
34.2
32
*
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
358.3
31.6
31
*
JJ2AT
NOMESCO Finland
Biopsy of liver with ultrasound guidance
61.4
28.0
32
6
WF049
NOMESCO Finland
Radiotherapy of metastasis
+∞
27.6
26
*
JN4AD
NOMESCO Finland
Body CT examination
14.4
26.1
45
38
A04AA01
ATC
ondansetron; systemic, rectal
40.9
26.0
32
9
N02AB03
ATC
fentanyl; nasal, sublingual, transdermal
11.9
18.9
35
34
R18
ICD-10 Finland
Ascites
29.5
18.2
24
9
D37.7
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Other digestive organs
25.3
18.2
25
11
C26.8
ICD-10 Finland
Malignant neoplasm: Overlapping lesion of digestive system
+∞
17.9
17
*
C61
ICD-10 Finland
Malignant neoplasm of prostate
+∞
17.9
17
*
8140/3-C61.9
ICD-O-3
Adenocarcinoma, NOS, of prostate gland
+∞
17.9
17
*
C80.92
ICD-10 Finland
Malignant tumor without specified localization adenocarcinoma
+∞
16.9
16
*
WZC00
NOMESCO Finland
Planning of intervention or health care consultation
3.7
16.0
83
300
C22.9
ICD-10 Finland
Malignant neoplasm: Liver, unspecified
+∞
15.8
15
*
116
Kela drug reimbursment
Prostate cancer
+∞
15.8
15
*
8140/3-C26.0
ICD-O-3
Adenocarcinoma, NOS, of intestinal tract, NOS
+∞
15.8
15
*
WZC30
NOMESCO Finland
Teaching
5.9
15.1
44
88
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
3.4
14.8
92
379
B01AB10
ATC
tinzaparin; parenteral
9.7
14.8
30
35
C79.5
ICD-10 Finland
Secondary malignant neoplasm of bone and bone marrow
+∞
14.7
14
*
JAH00
NOMESCO Finland
Laparotomy
12.6
14.7
26
23
WX302
NOMESCO Finland
Thoracal epidural anesthesy
14.7
14.6
24
18
WZC20
NOMESCO Finland
Multidisciplinary treatment meeting
24.1
14.5
20
9
D37.6
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Liver, gallbladder and bile ducts
32.3
14.1
18
6
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
+∞
13.7
13
*
8000/3-C26.0
ICD-O-3
Neoplasm, malignant of intestinal tract, NOS
+∞
13.7
13
*
8010/3-C26.9
ICD-O-3
Carcinoma, NOS, of gastrointestinal tract, NOS
+∞
12.6
12
*
C25.9
ICD-10 Finland
Malignant neoplasm: Pancreas, unspecified
+∞
11.5
11
*
8936/3-C26.9
ICD-O-3
Gastrointestinal stromal tumor of gastrointestinal tract, NOS
+∞
11.5
11
*
WD405
NOMESCO Finland
Simple antiboidy therapy of methastized malignancy
125.8
11.5
12
*
WD415
NOMESCO Finland
Demanding antibody therapy of methastized malignancy
125.8
11.5
12
*
JN3BD
NOMESCO Finland
Extensive abdominal CT
4.6
11.1
40
101
JA3AT
NOMESCO Finland
Cathetrisation of abdominal cavity with ultrasound guidance
45.6
11.0
13
*
L02AE02
ATC
leuprorelin; implant, parenteral
62.9
10.7
12
*
L03AA13
ATC
pegfilgrastim; parenteral
114.8
10.5
11
*
WF004
NOMESCO Finland
Palliative radiotherapy
+∞
10.5
10
*
A04AA55
ATC
palonosetron, combinations; systemic
+∞
10.5
10
*
A06AH03
ATC
naloxegol; oral
57.4
9.7
11
*
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
3.7
9.5
43
134
H01CB03
ATC
lanreotide; parenteral
+∞
9.4
9
*
C76.2
ICD-10 Finland
Malignant neoplasm of other and ill-defined sites: Abdomen
+∞
9.4
9
*
QX3AT
NOMESCO Finland
Ultrasound guided biopsy of subcutaneous tissue
+∞
9.4
9
*
WB113
NOMESCO Finland
Multiple adjuvant cytostatic therapy
+∞
9.4
9
*
166
Kela drug reimbursment
Dalteparin and tinzaparin (treatment for more than 6 months)
+∞
9.4
9
*
D77
ICPC
Malignant digestive neopl other/NOS
+∞
9.4
9
*
C49.49
ICD-10 Finland
Malignant tumor of connective tissue and soft tissue of the abdomen other or unspecified tumor
+∞
9.4
9
*
8090/3-C44.3
ICD-O-3
Basal cell carcinoma, NOS, of skin of other and unspecified parts of face
+∞
9.4
9
*
C25.0
ICD-10 Finland
Malignant neoplasm: Head of pancreas
+∞
9.4
9
*
TPH04
NOMESCO Finland
Cathetrisation of vein
2.9
9.1
63
264
B01AB05
ATC
enoxaparin; parenteral
2.6
9.1
80
390
K56.6
ICD-10 Finland
Other and unspecified intestinal obstruction
9.2
9.0
18
21
UJF32
NOMESCO Finland
Coloscopy
2.7
8.8
70
321
JN4CD
NOMESCO Finland
Very extensive body CT
17.1
8.6
13
8
R10.4
ICD-10 Finland
Other and unspecified abdominal pain
2.5
8.5
84
433
JN3AD
NOMESCO Finland
Abdominal CT examination
4.6
8.5
29
70
A04AD12
ATC
aprepitant; systemic
+∞
8.4
8
*
A79
ICPC
Malignancy NOS
+∞
8.4
8
*
Y77
ICPC
Malignant neoplasm prostate
+∞
8.4
8
*
C80.0
ICD-10 Finland
Malignant neoplasm, primary site unknown, so stated
+∞
8.4
8
*
XX3DW
NOMESCO Finland
Time consuming IT work
5.0
8.3
26
57
A49.9
ICD-10 Finland
Bacterial infection, unspecified
3.3
8.2
42
145
JAH01
NOMESCO Finland
Laparoscopy
8.2
8.0
17
22
D37.9
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Digestive organ, unspecified
25.9
7.6
10
*
WD115
NOMESCO Finland
Multiple cystostatic therapy of methastized malignancy
82.5
7.5
8
*
C78.0
ICD-10 Finland
Secondary malignant neoplasm of lung
+∞
7.3
7
*
PJ2AT
NOMESCO Finland
Biopsy of lymphnode with ultrasound guidance
+∞
7.3
7
*
189
Kela drug reimbursment
Imatinib
+∞
7.3
7
*
115
Kela drug reimbursment
Breast cancer
+∞
7.3
7
*
L02BG04
ATC
letrozole; oral
+∞
7.3
7
*
C56.00
ICD-10 Finland
Malignant tumor of the ovary without histology
+∞
7.3
7
*
YL1BD
NOMESCO Finland
Extensive CT examination of pelvis for dose design of radiotherapy
+∞
7.3
7
*
WB103
NOMESCO Finland
Simple adjuvant cytostatic therapy
+∞
7.3
7
*
C80.90
ICD-10 Finland
Malignant tumor without specified localization without histology
+∞
7.3
7
*
YN7BD
NOMESCO Finland
Extensive CT examination of spine for dose design of radiotherapy
+∞
7.3
7
*
TPH07
NOMESCO Finland
Cathetrisation of artery
3.6
7.0
31
95
JN1CG
NOMESCO Finland
Extensive MRI examination of upper part of abdomen with high intensity magnet
14.3
7.0
11
8
JF1AB
NOMESCO Finland
Passage examination of small bowell with X-ray
17.3
6.8
10
6
C44.31
ICD-10 Finland
Basocellular carcinoma of the skin on another or unspecified part of the face
41.2
6.8
8
*
L03AA02
ATC
filgrastim; parenteral
41.2
6.8
8
*
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
5.0
6.6
20
43
JFF10
NOMESCO Finland
Loop enterostomy
71.6
6.5
7
*
I26.9
ICD-10 Finland
Pulmonary embolism without mention of acute cor pulmonale
3.8
6.4
26
74
C16.9
ICD-10 Finland
Malignant neoplasm: Stomach, unspecified
+∞
6.3
6
*
8480/3-C26.9
ICD-O-3
Mucinous adenocarcinoma of gastrointestinal tract, NOS
+∞
6.3
6
*
C22.0
ICD-10 Finland
Malignant neoplasm: Liver cell carcinoma
+∞
6.3
6
*
C17.9
ICD-10 Finland
Malignant neoplasm: Small intestine, unspecified
+∞
6.3
6
*
8240/3-C26.9
ICD-O-3
Neuroendocrine tumor, NOS, of gastrointestinal tract, NOS
+∞
6.3
6
*
WD505
NOMESCO Finland
Simple enzyme inhibitor or similar therapy of methastized malignancy
+∞
6.3
6
*
C22.1
ICD-10 Finland
Malignant neoplasm: Intrahepatic bile duct carcinoma
+∞
6.3
6
*
L01XE01
ATC
[U] imatinib; oral
+∞
6.3
6
*
TPX10
NOMESCO Finland
Implantation of vascular injection port
8.0
6.2
13
17
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
284
237
22.88
308.19
4.6
1.4
127.9
4.0
ug/l
2.96
252
188
156
87
24.30
201.67
4.1
1.7
7112.8
93.0
u/ml
1.08
140
68
104
46
27.42
146.35
3.5
1.7
1074.1
97.8
u/ml
1.46
96
41
73
16
52.15
125.65
5.8
1.8
29.1
4.6
nmol/l
0.79
73
16
45
11
44.31
74.85
7.6
1.0
516.0
74.5
nmol/l
2.73
45
11
53
26
22.36
70.49
2.4
1.3
19.9
15.1
ug/l
0.79
53
26
393
2012
4.07
54.80
15.3
3.7
14.7
12.1
umol/l
1.49
380
1863
335
1797
3.09
38.12
10.5
3.6
31.0
35.0
g/l
21.70
322
1644
361
2106
2.95
33.72
18.7
5.7
4.7
4.4
e9/l
0.99
324
1814
260
1295
2.85
32.50
3.1
2.2
57.3
58.1
u/l
0.03
241
1180
122
425
3.38
28.23
5.4
2.8
283.1
242.2
u/l
1.02
117
397
117
413
3.30
26.38
3.4
2.2
15.4
8.3
umol/l
1.63
110
355
100
326
3.51
25.54
2.2
1.8
0.2
0.2
g/l
2.62
94
287
180
886
2.51
21.31
2.9
2.1
—
—
—
0
0
95
340
3.15
20.66
3.2
2.0
43.9
34.0
u/l
0.44
79
275
245
1402
2.31
20.48
8.6
2.1
2.3
2.4
mmol/l
1.79
235
1140
279
1740
2.18
18.32
5.2
3.7
—
—
—
0
0
81
285
3.15
18.04
1.5
1.6
—
—
—
0
0
91
346
2.94
17.69
6.5
5.7
9.6
11.4
mmol/l
1.27
86
320
296
1928
2.11
16.94
6.9
4.8
1.2
1.2
mmol/l
1.96
279
1688
164
851
2.30
16.68
7.0
2.3
2.5
2.4
mmol/l
3.55
153
725
208
1200
2.15
16.21
6.3
2.6
41.4
33.6
u/l
1.61
195
1137
413
3097
2.21
15.81
17.5
5.2
134.1
77.2
u/l
12.26
398
2815
313
2118
2.06
15.76
7.7
5.4
1.2
1.2
mmol/l
1.59
260
1796
53
165
3.44
14.32
1.6
1.6
0.8
1.4
ug/l
0.71
47
144
328
4166
0.50
14.30
3.9
5.4
2.6
2.6
mmol/l
0.14
288
3763
315
4050
0.50
14.17
3.7
4.8
4.5
4.5
mmol/l
0.19
278
3673
115
547
2.38
14.07
5.6
4.3
1.0
1.0
mmol/l
0.16
110
492
269
1787
1.96
13.62
6.0
5.3
21.1
26.4
%
11.41
254
1634
313
4006
0.51
13.29
3.5
4.8
1.4
1.5
mmol/l
0.38
276
3605
301
3863
0.53
12.17
3.4
4.3
1.3
1.3
mmol/l
0.33
262
3440
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
45
141
3.38
12.03
2.5
2.4
0.4
0.4
u/ml
0.18
29
79
311
3945
0.53
11.95
6.0
6.5
41.6
41.0
mmol/mol
0.57
277
3606
14
15
9.54
11.69
1.6
1.3
—
—
—
0
0
340
2532
1.85
11.29
5.4
4.0
6.9
6.9
mmol/l
0.05
323
2368
21
38
5.70
11.24
1.2
1.4
37543.3
15044.5
e6/l
—
9
23
122
653
2.10
11.00
2.2
1.7
31.3
29.5
s
0.73
122
625
23
48
4.95
10.56
1.3
1.3
—
—
—
0
0
22
46
4.93
10.08
1.2
1.4
967.5
1887.8
e6/l
0.75
13
33
339
4124
0.56
9.94
3.9
4.9
6.1
6.1
mmol/l
0.11
294
3686
31
94
3.43
8.73
1.3
1.4
—
—
—
0
0
108
603
1.97
8.53
2.5
2.3
2.2
2.3
g/l
0.22
102
554
101
563
1.96
7.98
2.6
2.4
22.1
22.3
%
0.02
79
471
28
85
3.41
7.89
2.5
2.1
89.9
87.6
%
0.20
28
79
37
136
2.84
7.59
1.2
1.2
—
—
—
0
0
115
683
1.86
7.48
2.5
2.3
12.0
12.5
umol/l
0.30
107
618
31
105
3.06
7.34
1.2
1.3
196.8
311.0
ug/g
2.41
19
57
94
529
1.93
7.20
5.4
5.6
12.7
11.3
kpa
1.86
94
504
94
529
1.93
7.20
5.4
5.6
4.9
5.1
kpa
1.35
94
505
94
532
1.92
7.07
5.3
5.6
1.3
1.4
mmol/l
0.20
77
411
208
1491
1.62
6.78
3.9
3.0
—
—
—
0
0
120
749
1.76
6.57
1.8
1.8
—
—
—
0
0
166
1145
1.63
6.23
3.7
2.9
1.5
0.5
e6/l
0.83
121
871
339
2766
1.56
6.08
5.4
4.7
46.6
3478.5
e6/l
—
8
51
60
1072
0.51
5.90
1.7
1.6
1.4
1.3
mmol/l
0.26
49
874
65
351
1.96
5.60
4.0
1.6
63.5
67.2
g/l
3.34
60
313
76
440
1.84
5.30
3.1
3.0
2.2
2.1
mmol/l
0.09
59
360
88
534
1.77
5.26
1.8
1.8
—
—
—
0
0
328
3792
0.68
4.73
4.1
4.6
2.0
2.3
mu/l
0.55
298
3387
85
535
1.69
4.45
1.8
1.8
—
—
—
0
0
8
9
8.99
4.29
1.9
1.8
—
—
—
0
0
6
237
0.25
4.29
1.2
1.9
—
—
—
0
0
37
183
2.09
4.08
3.4
3.5
1.7
1.4
mmol/l
0.57
37
176
98
660
1.58
3.92
3.5
2.8
3.1
2.6
e6/l
0.21
46
362
19
75
2.58
3.49
1.3
1.4
—
—
—
0
0
47
269
1.81
3.44
1.8
1.5
—
—
—
0
0
153
1163
1.43
3.40
2.1
2.2
3.2
3.0
mg/l
0.28
133
970
15
53
2.88
3.37
2.0
1.6
90.4
90.5
%
0.04
15
53
99
692
1.52
3.35
14.3
28.9
1.7
1.3
inr
0.90
11
96
20
83
2.46
3.33
2.4
2.3
16.3
16.1
%
—
6
41
35
619
0.54
3.25
1.1
1.2
1.4
11.5
u/ml
3.68
12
215
114
1502
0.70
2.96
4.0
4.0
21.2
7.7
mg/mmol
0.83
70
955
34
578
0.56
2.76
3.9
5.0
29.7
32.7
%
1.13
22
367
41
661
0.59
2.73
1.1
1.3
26.7
41.7
iu/ml
—
7
208
52
790
0.62
2.72
1.2
1.2
0.6
1.4
u/ml
2.03
16
214
97
712
1.44
2.57
3.4
2.6
1.8
1.4
e6/l
0.30
45
413
274
3107
0.77
2.44
3.5
3.7
15.2
15.0
pmol/l
0.57
243
2764
6
13
4.65
2.27
1.3
1.3
—
—
—
0
0
6
13
4.65
2.27
1.3
1.3
—
—
—
0
0
10
36
2.81
2.21
1.7
1.9
—
324.6
—
0
7
7
19
3.71
2.15
1.3
1.3
—
—
—
0
0
7
19
3.71
2.15
1.3
1.3
—
—
—
0
0
0
55
0.00
2.07
0.0
1.4
—
73.4
—
0
40
43
279
1.58
2.07
3.1
4.0
4.9
5.2
kpa
1.29
38
258
65
886
0.70
1.99
2.9
2.7
1.0
0.8
ug/l
0.42
46
605
171
2019
0.78
1.97
2.3
2.5
—
—
—
0
0
5
11
4.57
1.94
2.4
2.2
—
—
—
0
0
7
174
0.39
1.93
1.7
1.6
—
—
—
0
0
6
157
0.38
1.91
1.8
1.5
—
—
—
0
0
425
4509
0.77
1.90
44.2
20.5
121.1
134.4
g/l
49.61
413
4397
135
1096
1.30
1.90
4.7
4.1
0.0
0.0
estimate
0.00
45
309
425
4507
0.77
1.88
43.9
20.4
4.1
4.4
e12/l
29.52
404
4324
11
46
2.42
1.86
1.5
1.2
—
—
—
0
0
13
59
2.23
1.85
2.5
2.9
65.2
58.4
%
0.90
13
59
350
3794
0.80
1.85
30.0
13.0
75.8
73.4
ml/min/173m2
1.08
305
3027
104
1300
0.75
1.84
3.4
3.8
20.5
24.7
%
1.93
52
624
61
440
1.43
1.81
4.6
3.1
—
—
—
0
0
11
47
2.37
1.78
1.5
1.2
—
—
—
0
0
11
47
2.37
1.78
1.5
1.2
—
—
—
0
0
11
47
2.37
1.78
1.5
1.2
—
—
—
0
0
11
47
2.37
1.78
1.5
1.2
—
—
—
0
0
11
47
2.37
1.78
1.5
1.2
—
—
—
0
0
39
258
1.55
1.76
3.2
4.0
1.4
2.0
mmol/l
0.44
29
196
214
1865
1.24
1.64
3.6
4.1
31.8
62.0
ng/l
1.04
171
1410
5
14
3.59
1.62
1.2
1.0
—
—
—
0
0
16
84
1.93
1.61
1.2
1.4
—
—
—
0
0
16
84
1.93
1.61
1.4
1.2
—
—
—
0
0
6
20
3.02
1.58
1.5
1.4
—
—
—
0
0
17
92
1.87
1.57
1.2
1.3
—
—
—
0
0
12
57
2.13
1.56
2.5
2.5
5.2
4.4
e9/l
0.35
12
57
22
130
1.72
1.55
2.3
3.4
—
—
—
0
0
133
1106
1.26
1.54
4.0
2.4
3102.7
9524.6
umol/l
1.24
105
927
0
43
0.00
1.52
0.0
1.1
—
—
—
0
0
10
45
2.24
1.47
5.5
2.5
—
—
—
0
0
17
97
1.77
1.36
1.5
1.4
—
—
—
0
0
17
97
1.77
1.36
1.5
1.4
—
—
—
0
0
27
176
1.56
1.34
1.9
1.6
—
—
—
0
0
0
41
0.00
1.31
0.0
1.1
—
—
—
0
0
14
76
1.86
1.30
1.1
1.7
—
—
—
0
0
104
858
1.26
1.29
1.7
1.6
2.6
1.2
mg/l
2.88
94
680
35
244
1.46
1.28
1.5
2.2
1.6
1.2
%
1.23
35
244
34
236
1.47
1.28
1.6
2.2
0.9
0.7
%
1.47
34
231
0
33
0.00
1.16
0.0
1.0
—
—
—
0
0
8
40
2.01
1.12
1.1
1.3
—
—
—
0
0
142
1622
0.83
1.10
4.0
3.9
2.9
2.1
ug/l
1.00
123
1439
39
287
1.38
1.10
1.6
1.6
—
—
—
0
0
100
1178
0.82
1.06
1.6
1.6
22.5
20.8
nmol/l
0.36
87
993
177
1976
0.85
1.05
2.0
2.1
85.9
93.0
pmol/l
1.03
96
998
7
34
2.07
1.03
1.0
1.1
—
—
—
0
0
7
34
2.07
1.03
1.0
1.1
—
—
—
0
0
7
34
2.07
1.03
1.0
1.1
—
—
—
0
0
265
2449
1.15
0.93
4.0
2.9
120.5
50.0
u/l
5.66
246
2222
34
449
0.74
0.92
1.1
1.4
—
—
—
0
0
128
1453
0.85
0.91
2.3
2.2
134.9
271.4
u/l
1.82
119
1354
6
28
2.15
0.91
1.3
1.2
1.6
1.6
nmol/l
—
6
23
42
328
1.30
0.84
5.6
2.3
55.1
58.3
ml/min/173m2
0.33
16
138
10
57
1.77
0.84
1.5
1.3
0.6
0.6
nmol/l
—
10
52
23
163
1.43
0.83
1.6
1.5
—
—
—
0
0
0
25
0.00
0.79
0.0
1.0
—
1.1
—
0
16
424
4078
1.15
0.77
30.3
14.0
44.1
24.9
mg/l
14.67
400
3217
0
28
0.00
0.76
0.0
1.0
—
—
—
0
0
9
54
1.68
0.74
1.2
1.4
—
—
—
0
0
421
4355
0.87
0.74
34.3
17.4
4.0
4.0
mmol/l
0.78
407
4206
60
503
1.21
0.69
2.2
2.5
7.6
7.0
ug/l
0.05
46
433
5
91
0.55
0.67
1.0
1.1
—
17.2
—
0
8
421
4345
0.88
0.66
34.2
17.3
138.3
139.7
mmol/l
17.43
408
4200
10
62
1.62
0.65
1.1
1.4
—
—
—
0
0
421
4343
0.88
0.65
20.8
9.0
30.0
24.6
u/l
3.42
405
4118
215
2004
1.12
0.61
5.5
5.4
0.0
0.0
estimate
0.00
52
321
157
1707
0.89
0.61
2.1
2.2
70.3
78.1
nmol/l
2.84
139
1469
0
20
0.00
0.60
0.0
1.2
—
—
—
0
0
0
22
0.00
0.59
0.0
1.5
—
4.6
—
0
16
8
53
1.52
0.58
1.3
1.3
—
—
—
0
0
0
23
0.00
0.58
0.0
1.0
—
—
—
0
0
6
37
1.63
0.55
1.2
1.3
—
—
—
0
0
14
99
1.42
0.54
1.6
1.6
—
—
—
0
0
6
40
1.50
0.51
1.7
1.1
—
—
—
0
0
216
2036
1.10
0.48
4.3
4.0
0.0
0.0
estimate
0.50
51
320
11
154
0.71
0.47
1.0
1.0
—
—
—
0
0
11
77
1.44
0.45
1.0
1.2
—
—
—
0
0
37
311
1.20
0.45
1.6
2.7
121.6
129.6
g/l
1.49
37
305
212
2003
1.09
0.45
4.3
4.0
0.0
0.0
estimate
0.00
51
326
7
50
1.40
0.45
1.3
1.8
—
—
—
0
0
0
15
0.00
0.41
0.0
1.1
—
—
—
0
0
0
15
0.00
0.41
0.0
1.0
—
—
—
0
0
0
16
0.00
0.41
0.0
1.4
—
—
—
0
0
0
17
0.00
0.40
0.0
1.1
—
234.4
—
0
10
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
0
17
0.00
0.40
0.0
1.2
—
—
—
0
0
8
61
1.32
0.39
1.3
1.3
—
—
—
0
0
177
1676
1.08
0.35
2.8
2.7
322.1
136.2
ug/l
1.33
164
1504
55
611
0.89
0.33
18.0
7.8
—
—
—
0
0
115
1073
1.09
0.33
1.7
1.8
124731671.6
13557796.4
pmol/l
0.42
93
863
7
96
0.73
0.31
1.1
1.2
611.7
486.6
mg/l
—
7
91
164
1564
1.07
0.27
4.5
4.2
—
—
—
0
0
27
235
1.16
0.25
4.2
2.5
0.6
0.2
e6/l
0.42
27
227
15
123
1.22
0.25
1.2
1.2
—
—
—
0
0
15
123
1.22
0.25
1.2
1.2
—
—
—
0
0
5
40
1.25
0.22
1.2
1.1
—
—
—
0
0
349
3556
0.95
0.22
30.0
15.5
36.5
39.3
%
6.83
229
2233
5
42
1.19
0.21
1.2
1.5
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
0
11
0.00
0.21
0.0
1.9
—
—
—
0
0
0
11
0.00
0.21
0.0
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
1.1
—
—
—
0
0
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
9.7
—
0
13
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
7
58
1.21
0.18
1.1
1.1
—
—
—
0
0
19
166
1.15
0.18
1.2
1.3
—
—
—
0
0
7
59
1.19
0.18
1.3
1.4
—
—
—
0
0
8
69
1.16
0.16
1.3
1.3
—
—
—
0
0
7
86
0.81
0.14
1.1
1.2
4.0
4.0
mmol/l
—
7
81
16
178
0.90
0.11
1.1
1.3
—
—
—
0
0
5
44
1.14
0.10
1.4
1.2
—
—
—
0
0
5
44
1.14
0.10
1.4
1.7
—
—
—
0
0
162
1588
1.03
0.09
3.0
3.1
1579.9
1723.5
ng/l
0.15
142
1364
6
58
1.03
0.08
1.2
1.2
—
—
—
0
0
20
185
1.08
0.08
3.6
2.1
386.3
502.8
ug/l
0.17
20
173
106
1034
1.03
0.08
2.0
1.8
1227.8
1199.3
nmol/l
0.09
85
776
37
354
1.05
0.06
1.4
1.7
1.4
1.6
%
1.74
27
297
12
109
1.10
0.06
1.4
1.6
—
—
—
0
0
100
981
1.02
0.05
4.7
4.3
1.0
1.0
kg/l
0.32
14
143
96
944
1.02
0.04
3.6
4.1
85.9
263.4
ng/l
1.78
87
789
37
380
0.97
0.03
1.2
1.3
—
—
—
0
0
11
117
0.94
0.02
1.1
1.3
0.0
0.0
g/l
0.00
11
107
12
123
0.97
0.00
1.3
1.4
0.2
0.0
g/l
0.29
12
113
48
482
0.99
0.00
3.3
3.3
121.5
261.4
ng/l
4.02
43
448
306
3063
1.00
0.00
3.2
4.1
22.5
13.5
mm/h
8.32
282
2755
11
114
0.96
0.00
1.1
1.3
0.0
0.0
g/l
0.00
11
106
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
8
0.00
0.00
0.0
1.6
—
104.8
—
0
8
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
0.00
0.0
1.4
—
—
—
0
0
9
92
0.98
0.00
1.7
1.6
—
—
—
0
0
0
7
0.00
0.00
0.0
2.7
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
0.00
0.0
1.4
—
—
—
0
0
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
2.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
5
53
0.94
0.00
1.4
1.4
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
9
89
1.01
0.00
1.3
1.8
39.8
43.7
nmol/l
—
9
84
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
2.7
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: C3_DIGESTIVE_ORGANS_NAS_EXALLC – Malignant neoplasm of other and ill-defined digestive organs, excluding all cancers (controls excluding all cancers)
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).